Treatment of HBeAg-negative chronic hepatitis B with pegylated interferon

Research output: Contribution to journalArticle

Abstract

Serum HBeAg-negative chronic hepatitis B, which is usually a late stage of chronic hepatitis B virus infection, is difficult to treat, because it is characterized by fluctuating alanine transaminase values resulting in hepatitis flares, accelerated progression to cirrhosis and liver cancer. Antiviral treatment, either long-term nucleot(s)ide therapy or 1-year administration of pegylated interferon (PEG-IFN), is therefore necessary to limit the course of the disease. A sustained virological response to PEG-IFN is achieved in approximately 1/4 of the patients, with significant rates of HBsAg seroclearance. While waiting for the results of several studies whose goal is to improve the long-term efficacy of PEG-IFN, the treatment strategy can be optimized by a careful selection of patients, discontinuation of PEG-IFN as early as possible in primary non-responders and extended therapy (up to 96 weeks) in responders.

Original languageEnglish
Pages (from-to)90-94
Number of pages5
JournalLiver International
Volume31
Issue numberSUPPL. 1
DOIs
Publication statusPublished - Jan 2011

Fingerprint

Hepatitis B e Antigens
Chronic Hepatitis B
Interferons
Virus Diseases
Therapeutics
Liver Neoplasms
Hepatitis B Surface Antigens
Alanine Transaminase
Hepatitis B virus
Patient Selection
Hepatitis
Antiviral Agents
Fibrosis
Serum

Keywords

  • HBeAg-negative
  • Hepatitis B
  • PEG-IFNα sustained response

ASJC Scopus subject areas

  • Hepatology

Cite this

Treatment of HBeAg-negative chronic hepatitis B with pegylated interferon. / Lampertico, Pietro; Viganò, Mauro; Colombo, Massimo.

In: Liver International, Vol. 31, No. SUPPL. 1, 01.2011, p. 90-94.

Research output: Contribution to journalArticle

@article{544df4a7782447038fdab1721b154ffc,
title = "Treatment of HBeAg-negative chronic hepatitis B with pegylated interferon",
abstract = "Serum HBeAg-negative chronic hepatitis B, which is usually a late stage of chronic hepatitis B virus infection, is difficult to treat, because it is characterized by fluctuating alanine transaminase values resulting in hepatitis flares, accelerated progression to cirrhosis and liver cancer. Antiviral treatment, either long-term nucleot(s)ide therapy or 1-year administration of pegylated interferon (PEG-IFN), is therefore necessary to limit the course of the disease. A sustained virological response to PEG-IFN is achieved in approximately 1/4 of the patients, with significant rates of HBsAg seroclearance. While waiting for the results of several studies whose goal is to improve the long-term efficacy of PEG-IFN, the treatment strategy can be optimized by a careful selection of patients, discontinuation of PEG-IFN as early as possible in primary non-responders and extended therapy (up to 96 weeks) in responders.",
keywords = "HBeAg-negative, Hepatitis B, PEG-IFNα sustained response",
author = "Pietro Lampertico and Mauro Vigan{\`o} and Massimo Colombo",
year = "2011",
month = "1",
doi = "10.1111/j.1478-3231.2010.02386.x",
language = "English",
volume = "31",
pages = "90--94",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Treatment of HBeAg-negative chronic hepatitis B with pegylated interferon

AU - Lampertico, Pietro

AU - Viganò, Mauro

AU - Colombo, Massimo

PY - 2011/1

Y1 - 2011/1

N2 - Serum HBeAg-negative chronic hepatitis B, which is usually a late stage of chronic hepatitis B virus infection, is difficult to treat, because it is characterized by fluctuating alanine transaminase values resulting in hepatitis flares, accelerated progression to cirrhosis and liver cancer. Antiviral treatment, either long-term nucleot(s)ide therapy or 1-year administration of pegylated interferon (PEG-IFN), is therefore necessary to limit the course of the disease. A sustained virological response to PEG-IFN is achieved in approximately 1/4 of the patients, with significant rates of HBsAg seroclearance. While waiting for the results of several studies whose goal is to improve the long-term efficacy of PEG-IFN, the treatment strategy can be optimized by a careful selection of patients, discontinuation of PEG-IFN as early as possible in primary non-responders and extended therapy (up to 96 weeks) in responders.

AB - Serum HBeAg-negative chronic hepatitis B, which is usually a late stage of chronic hepatitis B virus infection, is difficult to treat, because it is characterized by fluctuating alanine transaminase values resulting in hepatitis flares, accelerated progression to cirrhosis and liver cancer. Antiviral treatment, either long-term nucleot(s)ide therapy or 1-year administration of pegylated interferon (PEG-IFN), is therefore necessary to limit the course of the disease. A sustained virological response to PEG-IFN is achieved in approximately 1/4 of the patients, with significant rates of HBsAg seroclearance. While waiting for the results of several studies whose goal is to improve the long-term efficacy of PEG-IFN, the treatment strategy can be optimized by a careful selection of patients, discontinuation of PEG-IFN as early as possible in primary non-responders and extended therapy (up to 96 weeks) in responders.

KW - HBeAg-negative

KW - Hepatitis B

KW - PEG-IFNα sustained response

UR - http://www.scopus.com/inward/record.url?scp=78650821453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650821453&partnerID=8YFLogxK

U2 - 10.1111/j.1478-3231.2010.02386.x

DO - 10.1111/j.1478-3231.2010.02386.x

M3 - Article

C2 - 21205144

AN - SCOPUS:78650821453

VL - 31

SP - 90

EP - 94

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - SUPPL. 1

ER -